Barth, T. and Zeman, F. and Helbig, H. and Gamulescu, M. -A. (2018) Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy. INTERNATIONAL OPHTHALMOLOGY, 38 (3). pp. 923-931. ISSN 0165-5701, 1573-2630
Full text not available from this repository. (Request a copy)Abstract
To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections. Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed. Eleven women and five men with a mean age of 35 years (SD 11, range 16-56 years) received intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1-9) were given per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both substances. The mean follow-up was 15 months (SD 11, range 6-40 months). BCVA improved in eight eyes (mean Delta +2.8 lines), remained stable in four eyes and decreased in four eyes (mean Delta -4.3 lines). CNV development is a frequent complication of PIC. Intravitreal anti-VEGF therapy seems to be safe and effective for PIC-related CNV.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | OCULAR HISTOPLASMOSIS; PHOTODYNAMIC THERAPY; SURGICAL-MANAGEMENT; CLINICAL-FEATURES; CASE SERIES; BEVACIZUMAB; RANIBIZUMAB; RESOLUTION; Choroidal neovascularization; Punctate inner choroidopathy; Intravitreal antiangiogenic therapy; Anti-VEGF (vascular endothelial growth factor) |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Augenheilkunde Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Klinische Studien |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 10 Mar 2020 12:26 |
| Last Modified: | 10 Mar 2020 12:26 |
| URI: | https://pred.uni-regensburg.de/id/eprint/14497 |
Actions (login required)
 |
View Item |
